Table 2.

Characteristics of Adolescents and Adults With De Novo Philadelphia Chromosome–Negative Precursor B-Lineage ALL (n = 282)

Characteristic	Modified Hyper-CVAD ± Rituximab								Hyper-CVAD Without Rituximab(n = 109)
	2: Without Intensification (n = 126)				1: With Intensification* (n = 47)
	CD20 Negative		CD20 Positive		CD20 Negative		CD20 Positive		CD20 Negative		CD20 Positive
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
No.	53		73		23		24		56		53
Age, years
≤ 30	13	25	25	34	8	35	6	25	25	45	19	36
31-59	30	57	29	40	9	39	9	38	26	46	25	47
≥ 60	10	19	19	26	6	26	9	38	5	9	9	17
Median	42		47		40		53		32		43
Range	15-75		15-79		18-80		19-83		13-70		16-78
Sex
Female	31	49	22	35	10	43	14	58	21	38	17	32
Zubrod performance status
0-1	48	91	60	82	19	83	15	63	44	79	33	62
2-3	5	9	13	18	4	17	9	38	12	21	20	38
Leukocyte count, ×109/L
< 5	26	49	42	58	11	48	18	75	20	36	25	47
5-29.9	17	32	22	30	4	17	4	17	24	43	20	38
≥ 30	10	19	9	12	8	35	2	8	12	21	8	15
Hemoglobin, g/dL
< 10	36	68	62	85	19	83	20	83	41	73	41	77
Platelet count, ×109/L
< 100	35	66	64	88	15	65	18	75	40	71	42	79
β-2 microglobulin, mg/dL
≥ 3	17/47	36	35/61	57	12/23	52	8/21	38	20/45	44	12/35	34
Lactate dehydrogenase, U/L
≥ 1,400	25	47	32	44	7	30	6	25	29	52	22	42
% peripheral blasts
Any	41	77	61	84	16	70	19	79	53	95	45	85
Karyotype (except IM; n = 50;58;21;23;48;45)
Diploid	22	44	30	52	12	54	12	52	18	38	19	42
Hyperdiploid	9	18	5	9	—		5	22	4	8	6	13
Hypodiploid	1	2	5	9	2	9	—		2	4	4	9
Translocation/other	18	36	18	31	7	33	6	26	24	50	16	36
CNS leukemia
Yes	3	6	9	12	—		1	4	1	2	3	6
Splenomegaly
Yes	9	17	15	21	2	9	3	12	11	20	18	34
Lymphadenopathy
Yes	12	23	21	29	8	35	5	21	18	32	14	26
Hepatomegaly
Yes	4	7	10	14	1	4	2	8	6	11	8	15
CNS relapse risk (n = 56;60;23;24;44;45)
Low	17	30	24	40	6	26	5	21	12	27	18	40
Indeterminate	6	10	6	10	7	30	12	50	1	2	1	2
High	33	59	30	50	10	43	7	29	31	70	26	58
Systemic risk classification
Low	13	25	26	36	2	9	6	25	18	32	16	30
High	40	75	46	64	21	91	18	75	38	68	37	70

NOTE. Includes precursor B-cell lineage ALL with data for CD20 expression (missing data for 31 cases treated with hyper-CVAD).

Abbreviations: ALL, acute lymphoblastic leukemia; Modified hyper-CVAD 1, anthracycline intensification with or without rituximab; Modified hyper-CVAD 2, no anthracycline intensification with or without rituximab; Hyper-CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; Negative, < 20% CD20 expression; Positive, ≥ 20% CD20 expression; IM, insufficient metaphases; CNS relapse risk (does not include CNS disease): low, proliferative index (S + G₂M) < 14% and LDH ≤ 1,400 U/L; High, S + G₂M ≥ 14% or LDH ≥ 1,400 U/L; Indeterminate, value unknown; Systemic risk classification: high risk, WBC > 5 × 10⁹/L, > 1 course to CR, Philadelphia chromosome or CNS disease; Low risk, none of these features.

^*Anthracycline intensification with cycle 2 of liposomal daunorubicin and cytarabine.